tiprankstipranks
Trending News
More News >
Kobayashi Pharmaceutical Co Ltd (JP:4967)
:4967

Kobayashi Pharmaceutical Co (4967) Price & Analysis

Compare
0 Followers

4967 Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

2.32%93.33%
Insiders
2.32%
Mutual Funds
― Other Institutional Investors
93.33% Public Companies and
Individual Investors

4967 FAQ

What was Kobayashi Pharmaceutical Co Ltd’s price range in the past 12 months?
Kobayashi Pharmaceutical Co Ltd lowest stock price was ¥4850.00 and its highest was ¥6350.00 in the past 12 months.
    What is Kobayashi Pharmaceutical Co Ltd’s market cap?
    Kobayashi Pharmaceutical Co Ltd’s market cap is $413.38B.
      When is Kobayashi Pharmaceutical Co Ltd’s upcoming earnings report date?
      Kobayashi Pharmaceutical Co Ltd’s upcoming earnings report date is Jul 31, 2025 which is in 48 days.
        How were Kobayashi Pharmaceutical Co Ltd’s earnings last quarter?
        Kobayashi Pharmaceutical Co Ltd released its earnings results on May 09, 2025. The company reported ¥21.86 earnings per share for the quarter, missing the consensus estimate of ¥50.023 by -¥28.163.
          Is Kobayashi Pharmaceutical Co Ltd overvalued?
          According to Wall Street analysts Kobayashi Pharmaceutical Co Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Kobayashi Pharmaceutical Co Ltd pay dividends?
            Kobayashi Pharmaceutical Co Ltd pays a Annually dividend of ¥44 which represents an annual dividend yield of 0.01%. See more information on Kobayashi Pharmaceutical Co Ltd dividends here
              What is Kobayashi Pharmaceutical Co Ltd’s EPS estimate?
              Kobayashi Pharmaceutical Co Ltd’s EPS estimate is 24.03.
                How many shares outstanding does Kobayashi Pharmaceutical Co Ltd have?
                Kobayashi Pharmaceutical Co Ltd has 78,050,000 shares outstanding.
                  What happened to Kobayashi Pharmaceutical Co Ltd’s price movement after its last earnings report?
                  Kobayashi Pharmaceutical Co Ltd reported an EPS of ¥21.86 in its last earnings report, missing expectations of ¥50.023. Following the earnings report the stock price went down -0.84%.
                    Which hedge fund is a major shareholder of Kobayashi Pharmaceutical Co Ltd?
                    Currently, no hedge funds are holding shares in JP:4967

                    Company Description

                    Kobayashi Pharmaceutical Co Ltd

                    Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells consumer products in Japan and internationally. The company provides products in the areas of healthcare, skincare, body warmer, and household. It also offers Ammeltz, a topical analgesic; Inochi no Haha, a women's health medicine; Shirt Coola, a summer cooling spray for cloths; Sarasaty lingerie soap; Bluelet Decoral, a toilet bowl cleaner and freshener; Nightmin Nasal Respiration Tape; Naishitol, a Chinese medicine; Eaude Muge, a medicated lotion for preventing acne; Itoyoji, a dental floss pick; BreathCare, an oral breath freshener capsule; Eybon, an eye wash; Netsusama sheet, a cooling gel sheet for forehead; and Sawaday, a toilet air freshener. Additionally, the company manufactures and sells pharmaceuticals, quasi-drugs, cosmetics, hygiene and paper products, health foods, and processed synthetic resin products; markets nutritional supplements and skin care products through sales promotional campaigns, such as advertising and direct mail; and sells skincare products, health foods, and other items through e-commerce channels. Further, it engages in transportation, real estate management, and advertising planning and production businesses. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.

                    4967 Stock 12 Month Forecast

                    Average Price Target

                    ¥5,149.77
                    ▼(-7.73%Downside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4883":"¥4,883","5331":"¥5,331","5779":"¥5,779","6227":"¥6,227","6675":"¥6,675"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5200.000000004992,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥5.20K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5149.7695852584,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥5.15K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5100.000000004896,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥5.10K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4883,5331,5779,6227,6675],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Sep<br/>2024","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5289,5282.15384615423,5275.30769230846,5268.46153846269,5261.615384616921,5254.76923077115,5247.923076925381,5241.076923079611,5234.230769233842,5227.384615388071,5220.538461542302,5213.692307696532,5206.846153850762,{"y":5200.000000004992,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5289,5278.2899680968,5267.5799361936,5256.8699042904,5246.1598723872,5235.449840484,5224.7398085808,5214.0297766776,5203.3197447744005,5192.6097128712,5181.899680968,5171.1896490648005,5160.4796171616,{"y":5149.7695852584,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5289,5274.461538461915,5259.92307692383,5245.384615385745,5230.84615384766,5216.307692309575,5201.769230771491,5187.230769233405,5172.692307695321,5158.153846157235,5143.615384619151,5129.076923081066,5114.538461542981,{"y":5100.000000004896,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6674.047,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6610.157,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5879.845,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4884.144,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5327.443,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5336.289,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5249.344,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5847.571,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5510.821,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5510.821,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5477.146,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5500,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5289,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Kose
                    Lion
                    Paltac
                    Pola Orbis Holdings
                    Rohto Pharmaceutical Co
                    Popular Stocks
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis